Journal Mobile Options
Table of Contents
Vol. 80, No. 2-3, 2007
Issue release date: August 2007
Pharmacology 2007;80:65–119
(DOI:10.1159/000103923)

Explaining the Escalation of Drug Use in Substance Dependence: Models and Appropriate Animal Laboratory Tests

Zernig G. · Ahmed S.H. · Cardinal R.N. · Morgan D. · Acquas E. · Foltin R.W. · Vezina P. · Negus S.S. · Crespo J.A. · Stöckl P. · Grubinger P. · Madlung E. · Haring C. · Kurz M. · Saria A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Escalation of drug use, a hallmark of drug dependence, has traditionally been interpreted as reflecting the development of tolerance to the drug’s effects. However, on the basis of animal behavioral data, several groups have recently proposed alternative explanations, i.e. that such an escalation of drug use might not be based on (1) tolerance, but rather be indicative of (2) sensitization to the drug’s reinforcing effect, (3) reward allostasis, (4) an increase in the incentive salience of drug-associated stimuli, (5) an increase in the reinforcing strength of the drug reinforcer relative to alternative reinforcers, or (6) habit formation. From the pharmacological perspective, models 1–3 allow predictions about the change in the shape of drug dose-effect curves that are based on mathematically defined models governing receptor-ligand interaction and signal transduction. These predictions are tested in the present review, which also describes the other currently championed models for drug use escalation and other components of apparent ‘reinforcement’ (in its original meaning, like ‘tolerance’ or ‘sensitization’, a purely descriptive term). It evaluates the animal experimental approaches employed to support or prove the existence of each of the models and reinforcement components, and recapitulates the clinical evidence, which strongly suggests that escalation of drug use is predominantly based on an increase in the frequency of intoxication events rather than an increase in the dose taken at each intoxication event. Two apparent discrepancies in animal experiments are that (a) sensitization to overall reinforcement has been found more often for psychostimulants than for opioids, and that (b) tolerance to the reinforcing and other effects has been observed more often for opioids than for cocaine. These discrepancies are resolved by the finding that cocaine levels seem to be more tightly regulated at submaximum reinforcing levels than opioid levels are. Consequently, animals self-administering opioids are more likely to expose themselves to higher above-threshold doses than animals self-administering psychostimulants, rendering the development of tolerance to opioids more likely than tolerance to psychostimulants. The review concludes by making suggestions on how to improve the current behavioral experimental approaches.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Acquas E, DiChiara G: Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 1992;58:1620–1625.
  2. Aguilar de Arcos F, Verdejo-Garcia A, Peralta-Ramirez MI, Sanchez-Barrera M, Perez-Garcia M: Experience of emotions in substance abusers exposed to images containing neutral, positive, and negative affective stimuli. Drug Alcohol Depend 2005;78:159–167.
  3. Ahmadi J, Majdi B, Mahdavi S, Mohagheghzadeh M: Mood disorders in opioid-dependent patients. J Affect Disord 2004;82:139–142.
  4. Ahmed SH: Neuroscience. Addiction as compulsive reward prediction. Science 2004;306:1901–1902.
  5. Ahmed SH: Imbalance between drug and non-drug reward availability: a major risk factor for addiction. Eur J Pharmacol 2005;526:9–20.
  6. Ahmed SH, Kenny PJ, Koob GF, Markou A: Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 2002;5:625–626.
  7. Ahmed SH, Koob GF: Transition from moderate to excessive drug intake: change in hedonic set point. Science 1998;282:298–300.
  8. Ahmed SH, Koob GF: Vertical shifts in dose-injection curves reflect reward allostasis, not sensitization. Psychopharmacology 2004;171:354–355.
  9. Ahmed SH, Koob GF: Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology (Berl) 2005;180:473–490.
  10. Ahmed SH, Lin D, Koob GF, Parsons LH: Escalation of cocaine self-administration does not depend on altered cocaine-induced nucleus accumbens dopamine levels. J Neurochem 2003;86:102–113.
  11. Akers RL, Krohn MD, Lanza-Kaduce L, Radosevich M: Social learning and deviant behavior: a specific test of a general theory. Am Sociol Rev 1979;44:636–655.
  12. Amato L, Davoli M, Ferri M, Ali R: Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2002;(1):CD003409.
  13. Ambre JJ, Belknap SM, Nelson J, Ruo TI, Shin SG, Atkinson AJ Jr: Acute tolerance to cocaine in humans. Clin Pharmacol Ther 1988;44:1–8.
  14. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4 (DSM-IV). Washington,American Psychiatric Association, 1994.
  15. Arroyo M, Markou A, Robbins TW, Everitt BJ: Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous access to cocaine. Psychopharmacology (Berl) 1998;140:331–344.
  16. Arunlakshana O, Schild HO: Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48–57.
  17. Bakken K, Landheim AS, Vaglum P: Primary and secondary substance misusers: do they differ in substance-induced and substance-independent mental disorders? Alcohol Alcohol 2003;38:54–59.
  18. Balleine BW, Dickinson A: Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Neuropharmacology 1998;37:407–419.
  19. Bardo MT, Rowlett JK, Harris MJ: Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci Biobehav Rev 1995;19:39–51.
  20. Bardo MT, Valone JM, Bevins RA: Locomotion and conditioned place preference produced by acute intravenous amphetamine: role of dopamine receptors and individual differences in amphetamine self-administration. Psychopharmacology (Berl) 1999;143:39–46.
  21. Bartlett E, Hallin A, Chapman B, Angrist B: Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability? Neuropsychopharmacology 1997;16:77–82.
  22. Bechara A, Damasio H, Damasio AR: Emotion, decision making and the orbitofrontal cortex. Cereb Cortex 2000;10:295–307.
  23. Berridge KC: Pleasure, pain, desire, and dread: hidden core processes of emotion; in Kahneman D, Diener E, Schwarz N (eds): Well-Being: Foundations of Hedonic Psychology. New York, Russell Sage Foundation, 1999, pp 525–557.
  24. Berridge KC: Pleasures of the brain. Brain Cogn 2003;52:106–128.
  25. Berridge KC, Pecina S: Benzodiazepines, appetite, and taste palatability. Neurosci Biobehav Rev 1995;19:121–131.
  26. Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998;28:309–369.
  27. Berridge KC, Robinson TE: Parsing reward. Trends Neurosci 2003;26:507–513.
  28. Bertalmio AJ, Woods JH: Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis. J Pharmacol Exp Ther 1989;251:455–460.
  29. Bhargava HN, Rahmani NH, Villar VM, Larsen AK: Effects of naltrexone on pharmacodynamics and pharmacokinetics of intravenously administered morphine in the rat. Pharmacology 1993;46:66–74.
  30. Bickel WK, DeGrandpre RJ, Higgins ST, Hughes JR: Behavioral economics of drug self-administration. I. Functional equivalence of response requirement and drug dose. Life Sci 1990;47:1501–1510.
  31. Bindra D: How adaptive behavior is produced: a perceptual-motivational alternative to response-reinforcement. Behav Brain Sci 1978;1:41–91.

    External Resources

  32. Black JW, Leff P: Operational models of pharmacological agonism. Proc R Soc Lond B 1983;220:141–162.
  33. Black JW, Leff P, Shankley NP, Wood J: An operational model of pharmacological antagonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 1985;84:561–571.
  34. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, et al: Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006;63:1386–1395.
  35. Bozarth MA: Methods of Assessing the Reinforcing Properties of Abused Drugs. New York, Springer, 1987.
  36. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE: Acute effects of cocaine on human brain activity and emotion. Neuron 1997;19:591–611.
  37. Brower KJ, Hierholzer R, Maddahian E: Recent trends in cocaine abuse in a VA psychiatric population. Hosp Community Psychiatry 1986;37:1229–1234.
  38. Brunton LL, Lazo JS, Parker KL: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, ed 11. New York, McGraw-Hill, 2006.
  39. Cadoni C, Di Chiara G: Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol 2000;387:R23–R25.
  40. Cador M, Bjijou Y, Stinus L: Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine. Neuroscience 1995;65:385–395.
  41. Caine SB, Negus SS, Mello NK: Effects of dopamine D(1-like) and D(2-like) agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect functions. Psychopharmacology (Berl) 2000;148:41–51.
  42. Caine SB, Negus SS, Mello NK, Bergman J: Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 1999;291:353–360.
  43. Cardinal RN, Parkinson JA, Hall J, Everitt BJ: Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev 2002;26:321–352.
  44. Carrera MR, Schulteis G, Koob GF: Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Psychopharmacology (Berl) 1999;144:111–120.
  45. Catania AC: Contemporary Research in Operant Behavior. Glenview, Scott, Foresman & Co, 1968.
  46. Catania AC: Learning. Englewood Cliffs, Prentice Hall, 1979.
  47. Catania AC: Learning, ed 3. Englewood Cliffs, Prentice Hall, 1992.
  48. Chen SA, O’Dell LE, Hoefer ME, Greenwell TN, Zorrilla EP, Koob GF: Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology 2006;31:2692–2707.
  49. Chen ZR, Somogyi AA, Reynolds G, Bochner F: Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991;31:381–390.
  50. Cho AK, Melega WP, Kuczenski R, Segal DS: Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 2001;39:161–166.
  51. Chow MJ, Ambre JJ, Ruo TI, Atkinson AJ Jr, Bowsher DJ, Fischman MW: Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin Pharmacol Ther 1985;38:318–324.
  52. Colwill RM, Rescorla RA: Instrumental responding remains sensitive to reinforcer devaluation after extensive training. J Exp Psychol: Anim Behav Processes 1985;11:520–536.

    External Resources

  53. Colwill RM, Rescorla RA: The role of response-reinforcer associations increases throughout extended instrumental training. Anim Learning Behav 1988;16:105–111.
  54. Colwill RM, Triola SM: Instrumental responding remains under the control of the consequent outcome after extended training. Behav Processes 2002;57:51–64.
  55. Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW: Effects of repeated oral methamphetamine administration in humans. Psychopharmacology (Berl) 2001;155:397–404.
  56. Cone EJ: Pharmacokinetics and pharmacodynamics of cocaine. J Anal Toxicol 1995;19:459–478.
  57. Cox BM: Opioid Receptor–G Protein Interactions: Acute and Chronic Effects of Opioids. New York, Springer, 1993.
  58. Cox BM, Werling LL: Opioid Tolerance and Dependence. New York, Academic Press, 1991.
  59. Crespo JA, Panlilio LV, Schindler CW, Sturm K, Saria A, Zernig G: Peri-response pharmakokinetics of remifentanil during a self-administration session indicates that blood or brain levels are not titrated. Ann NY Acad Sci 2006;1074:497–504.
  60. Crespo JA, Sturm K, Saria A, Zernig G: Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. Psychopharmacology 2005;183:201–209.
  61. Crespo JA, Sturm K, Saria A, Zernig G: Activation of muscarinic and nicotinic acetylcholine receptors in the nucleus accumbens core is necessary for the acquistion of drug reinforcement. J Neurosci 2006;26:6004–6010.
  62. Czoty PW, Martelle JL, Nader MA: Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in nonhuman primates. Drug Alcohol Depend 2006;85:213–220.
  63. Daw ND, Niv Y, Dayan P: Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control. Nat Neurosci 2005;8:1704–1711.
  64. Deroche V, Le Moal M, Piazza PV: Cocaine self-administration increases the incentive motivational properties of the drug in rats. Eur J Neurosci 1999;11:2731–2736.
  65. Deroche-Gamonet V, Belin D, Piazza PV: Evidence for addiction-like behavior in the rat. Science 2004;305:1014–1017.
  66. Desai RI, Kopajtic TA, French D, Newman AH, Katz JL: Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs. J Pharmacol Exp Ther 2005;315:397–404.
  67. deWit H, Stewart J: Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 1981;75:134–143.
  68. DiChiara G, Bassareo V, Fenu S, DeLuca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D: Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004;47:227–241.
  69. Dickinson A: Actions and habits – the development of behavioral autonomy. Phil Trans R Soc London B 1985;308:67–78.

    External Resources

  70. Dickinson A: Instrumental conditioning; in Mackintosh NJ (ed): Animal Learning and Cognition. San Diego, Academic Press, 1994, pp 45–79.
  71. Dickinson A, Nicholas DJ, Adams CD: The effect of the instrumental training contingency on susceptibility to reinforcer devaluation. Q J Exp Psychol B 1983;35:35–51.

    External Resources

  72. Dickinson A, Wood N, Smith JW: Alcohol seeking by rats: action or habit? Q J Exp Psychol B 2002;55:331–348.
  73. Dinsmoor JA: The etymology of basic concepts in the experimental analysis of behavior. J Exp Anal Behav 2004;82:311–316.
  74. Dole VP: Methadone treatment and the acquired immunodeficiency syndrome epidemic. JAMA 1989;262:1681.
  75. Emmett-Oglesby MW, Lane JD: Tolerance to the reinforcing effects of cocaine. Behav Pharmacol 1992;3:193–200.
  76. Emmett-Oglesby MW, Peltier RL, Depoortere RY, Pickering CL, Hooper ML, Gong YH, Lane JD: Tolerance to self-administration of cocaine in rats: time course and dose-response determination using a multi-dose method. Drug Alcohol Depend 1993;32:247–256.
  77. Evans SM, Cone EJ, Henningfield JE: Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 1996;279:1345–1356.
  78. Evans SM, Haney M, Foltin RW: The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl) 2002;159:397–406.
  79. Everitt BJ, Robbins TW: Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour. Psychopharmacology (Berl) 2000;153:17–30.
  80. Everitt BJ, Robbins TW: Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005;8:1481–1489.
  81. Fibiger HC: Mesolimbic dopamine: an analysis of its role in motivated behavior. Semin Neurosci 1993;5:321–327.
  82. Fichter MM, Narrow WE, Roper MT, Rehm J, Elton M, Rae DS, Locke BZ, Regier DA: Prevalence of mental illness in Germany and the United States. Comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program. J Nerv Ment Dis 1996;184:598–606.
  83. Field M, Eastwood B, Bradley BP, Mogg K: Selective processing of cannabis cues in regular cannabis users. Drug Alcohol Depend 2006;85:75–82.
  84. Fischer G, Jagsch R, Eder H, Gombas W, Etzersdorfer P, Schmidl-Mohl K, Schatten C, Weninger M, Aschauer HN: Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999;94:231–239.
  85. Fischman MW: Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs. NIDA Res Monogr 1989;92:211–230.
  86. Fischman MW, Schuster CR, Javaid J, Hatano Y, Davis J: Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther 1985;235:677–682.
  87. Flory GS, Woods JH: The ascending limb of the cocaine dose-response curve for reinforcing effect in rhesus monkeys. Psychopharmacology (Berl) 2003;166:91–94.
  88. Foltin RW, Fischman MW: Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther 1991;257:247–261.
  89. Foltin RW, Haney M: Conditioned effects of environmental stimuli paired with smoked cocaine in humans. Psychopharmacology (Berl) 2000;149:24–33.
  90. Fox HC, Parrott AC, Turner JJ: Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 2001;15:273–281.
  91. Furchgott RF, Bursztyn P: Comparison of dissociation constants and or relative efficacies of selected agonists acting on parasympathetic receptors. Ann NY Acad Sci 1967;144:882–899.
  92. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ, et al: Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 2000;157:1789–1798.
  93. Garcia J: Mind is back in control of pavlovian and skinnerian responses: was it ever away? J Behav Ther Exp Psychiatry 1995;26:229–234.
  94. Gawin FH, Kleber HD: Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986;43:107–113.
  95. Geist TD, Ettenberg A: A simple method for studying intravenous drug reinforcement in a runway. Pharmacol Biochem Behav 1990;36:703–706.
  96. Geist TD, Ettenberg A: Concurrent positive and negative goalbox events produce runway behaviors comparable to those of cocaine-reinforced rats. Pharmacol Biochem Behav 1997;57:145–150.
  97. Glowa JR, Fantegrossi WE: Effects of dopaminergic drugs on food- and cocaine-maintained responding. IV. Continuous cocaine infusions. Drug Alcohol Depend 1997;45:71–79.
  98. Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642–1652.
  99. Gomez TH, Roache JD, Meisch RA: Relative reinforcing effects of different benzodiazepine doses for rhesus monkeys. Drug Alcohol Depend 2002;68:275–283.
  100. Green TA, Gehrke BJ, Bardo MT: Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules. Psychopharmacology (Berl) 2002;162:373–378.
  101. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV: Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 1991;103:154–161.
  102. Griffiths RR, Richards WA, McCann U, Jesse R: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006;187:268–283.
  103. Griffiths RR, Wurster RM, Brady JV: Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev 1975;27:357–365.
  104. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A: Goodman & Gilman’s The Pharmacological B of Therapeutics, ed 9. New York, McGraw-Hill, 1996.
  105. Hatsukami DK, Pentel PR, Glass J, Nelson R, Brauer LH, Crosby R, Hanson K: Methodological issues in the administration of multiple doses of smoked cocaine-base in humans. Pharmacol Biochem Behav 1994;47:531–540.
  106. Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C: Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 1991;41:89–125.
  107. Helmus TC, Tancer M, Johanson CE: Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. Exp Clin Psychopharmacol 2005;13:348–356.
  108. Hemby SE, Co C, Koves TR, Smith JE, Dworkin SI: Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat. Psychopharmacology (Berl) 1997;133:7–16.
  109. Herrnstein RJ: Melioration: a theory of distributed choice. J Econ Perspect 1991;5:137–140.

    External Resources

  110. Heyman GM: Resolving the contradictions of addiction. Behav Brain Sci 1996;19:561–610.

    External Resources

  111. Hutcheson DM, Everitt BJ, Robbins TW, Dickinson A: The role of withdrawal in heroin addiction: enhances reward or promotes avoidance? Nat Neurosci 2001;4:943–947.
  112. Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ: Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J Neurosci 2000;20:7489–7495.
  113. Izenwasser S, Cox BM: Inhibition of dopamine uptake by cocaine and nicotine: tolerance to chronic treatments. Brain Res 1992;573:119–125.
  114. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.
  115. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685–691.
  116. Jufer RA, Wstadik A, Walsh SL, Levine BS, Cone EJ: Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol 2000;24:467–477.
  117. Kalant H, LeBlanc AE, Gibbins RJ: Tolerance to, and dependence on, some non-opiate psychotropic drugs. Pharmacol Rev 1971;23:135–191.
  118. Kalivas PW, Duffy P: Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse 1990;5:48–58.
  119. Kalivas PW, Duffy P: Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 1993;13:266–275.
  120. Kalivas PW, McFarland K: Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) 2003;168:44–56.
  121. Katz JL, Higgins ST: What is represented by vertical shifts in self-administration dose-response curves? Psychopharmacology 2004;171:360–361.
  122. Katzung BG: Basic and Clinical Pharmacology. Englewood Cliffs, Prentice-Hall, 1991.
  123. Kenakin TP: Pharmacologic Analysis of Drug-Receptor Interaction, ed 2. New York, Raven Press, 1993.
  124. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF: Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 2006;26:5894–5900.
  125. Kenny PJ, Polis I, Koob GF, Markou A: Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats. Eur J Neurosci 2003;17:191–195.
  126. Kim JH, Austin JD, Tanabe LM, Creekmore E, Vezina P: Activation of group II mGlu receptors blocks the enhanced drug taking induced by previous exposure to amphetamine. Eur J Neurosci 2005;21:295–300.
  127. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L: Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 2006;186:48–53.
  128. Kleven MS, Woolverton WL: Effects of exposure regimen on changes in sensitivity to the effects of cocaine on schedule-controlled behavior in rhesus monkeys. Behav Brain Res 1996;79:101–107.
  129. Koob G: Allostatic view of motivation: implications for psychopathology; in Bevins R, Bardo MT (eds): Motivational Factors in the Etiology of Drug Abuse. Lincoln, University of Nebraska Press, 2003, pp 1–20.
  130. Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 1997;278:52–58.
  131. Koob GF, Le Moal M: Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001;24:97–129.
  132. Koob GF, Maldonado R, Stinus L: Neural substrates of opiate withdrawal. Trends Neurosci 1992;15:186–191.
  133. Kreek MJ, LaForge KS, Butelman E: Pharmacotherapy of addictions. Nat Rev Drug Discov 2002;1:710–726.
  134. Kumor KM, Sherer MA, Gomez J, Cone E, Jaffe JH: Subjective response during continuous infusion of cocaine. Pharmacol Biochem Behav 1989;33:443–452.
  135. Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, Goldberg SR: The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 1991;259:1165–1173.
  136. Lecca D, Cacciapaglia F, Valentini V, Acquas E, Di Chiara G: Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. Psychopharmacology (Berl) 2007;191:653-667.
  137. Lecca D, Cacciapaglia F, Valentini V, Di Chiara G: Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212–2 self-administration. Psychopharmacology (Berl) 2006;188:63–74.
  138. Lecca D, Cacciapaglia F, Valentini V, Gronli J, Spiga S, Di Chiara G: Preferential increase of extracellular dopamine in the rat nucleus accumbens shell as compared to that in the core during acquisition and maintenance of intravenous nicotine self-administration. Psychopharmacology (Berl) 2006;184:435–446.
  139. Leinonen E, Lepola U, Koponen H, Kinnunen I: The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18:111–117.
  140. Lenoir M, Ahmed SH: Heroin-induced reinstatement is specific to compulsive heroin use and dissociable from heroin reward and sensitization. Neuropsychopharmacology 2007;32:616–624.
  141. Li DH, Depoortere RY, Emmett-Oglesby MW: Tolerance to the reinforcing effects of cocaine in a progressive ratio paradigm. Psychopharmacology (Berl) 1994;116:326–332.
  142. Liu Y, Roberts DC, Morgan D: Effects of extended-access self-administration and deprivation on breakpoints maintained by cocaine in rats. Psychopharmacology (Berl) 2005;179:644–651.
  143. Liu Y, Roberts DC, Morgan D: Sensitization of the reinforcing effects of self-administered cocaine in rats: effects of dose and intravenous injection speed. Eur J Neurosci 2005;22:195–200.
  144. Lorrain DS, Arnold GM, Vezina P: Previous exposure to amphetamine increases incentive to obtain the drug: long-lasting effects revealed by the progressive ratio schedule. Behav Brain Res 2000;107:9–19.
  145. Madlung E, Haring C, Crespo JA, Saria A, Grubinger P, Zernig G: Methadone doses upon multiple readmissions to inpatient detoxification: clinical evidence for moderate opioid tolerance. Pharmacology 2006;78:38–43.
  146. Martin WR, Sloan JW, Sapira JD, Jasinski DR: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245–258.
  147. Martin-Soelch C, Leenders KL, Chevalley AF, Missimer J, Kunig G, Magyar S, Mino A, Schultz W: Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev 2001;36:139–149.
  148. Mateo Y, Lack CM, Morgan D, Roberts DC, Jones SR: Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology 2005;30:1455–1463.
  149. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2002;(4):CD002209.
  150. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002207.
  151. McFarland K, Davidge SB, Lapish CC, Kalivas PW: Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 2004;24:1551–1560.
  152. Meisch RA, Lemaire GA: Drug self-administration; in vanHaaren F, Huston JP (eds): Techniques in the Behavioral and Neural Sciences. Amsterdam, Elsevier, 1993, pp 257–300.
  153. Melis M, Spiga S, Diana M: The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 2005;63:101–154.
  154. Mello NK, Negus SS: Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996;14:375–424.
  155. Mendrek A, Blaha CD, Phillips AG: Pre-exposure of rats to amphetamine sensitizes self-administration of this drug under a progressive ratio schedule. Psychopharmacology (Berl) 1998;135:416–422.
  156. Miles FJ, Everitt BJ, Dickinson A: Oral cocaine seeking by rats: action or habit? Behav Neurosci 2003;117:927–938.
  157. Moolchan ET, Cone EJ, Wstadik A, Huestis MA, Preston KL: Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. J Anal Toxicol 2000;24:458–466.
  158. Morgan D, Brebner K, Lynch WJ, Roberts DC: Increases in the reinforcing efficacy of cocaine after particular histories of reinforcement. Behav Pharmacol 2002;13:389–396.
  159. Morgan D, Liu Y, Roberts DC: Rapid and persistent sensitization to the reinforcing effects of cocaine. Neuropsychopharmacology 2006;31:121–128.
  160. Morgan D, Roberts DC: Sensitization to the reinforcing effects of cocaine following binge-abstinent self-administration. Neurosci Biobehav Rev 2004;27:803–812.
  161. Morgan D, Smith MA, Roberts DC: Binge self-administration and deprivation produces sensitization to the reinforcing effects of cocaine in rats. Psychopharmacology 2005;178:309–316.
  162. Mutschler NH, Covington HE III, Miczek KA: Repeated self-administered cocaine ‘binges’ in rats: effects on cocaine intake and withdrawal. Psychopharmacology 2001;154:292–300.
  163. Negus SS: Assessment of cocaine ‘dependence’ and ‘withdrawal’ in a drug vs food choice procedure in rhesus monkeys. Presentation at the International Study Group Investigating Drugs As Reinforcers (ISGIDAR) meeting 2006.
  164. Negus SS: Choice between heroin and food in non-dependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine and methadone. J Pharmacol Exp Ther 2006;317:711–723.
  165. Negus SS, Mello NK: Effects of chronic D-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 2003;167:324–332.
  166. Negus SS, Mello NK: Effects of chronic D-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 2003;70:39–52.
  167. Negus SS, Mello NK: Effects of chronic methadone treatment on cocaine- and food-maintained responding under second-order, progressive-ratio and concurrent choice schedules in rhesus monkeys. Drug Alcohol Dep 2004;74:297–309.
  168. Negus SS, Mello NK, Caine SB: The utility of ‘tolerance’ as a concept in the study of drug self-administration. Psychopharmacology 2004;171:362–363.
  169. Nelson A, Killcross S: Amphetamine exposure enhances habit formation. J Neurosci 2006;26:3805–3812.
  170. Nestler EJ, Hope BT, Widnell KL: Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993;11:995–1006.
  171. O’Brien CP: Drug addiction and drug abuse; in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw-Hill, 1996, pp 557–577.
  172. O’Brien CP: Drug addiction and drug abuse; in Brunton LL, Lazo JS, Parker KL (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 11. New York, McGraw-Hill, 2006, pp 607–627.
  173. Olmstead MC, Parkinson JA, Miles FJ, Everitt BJ, Dickinson A: Cocaine-seeking by rats: regulation, reinforcement and activation. Psychopharmacology (Berl) 2000;152:123–131.
  174. Pan HT, Menacherry S, Justice J Jr: Differences in the pharmacokinetics of cocaine in naive and cocaine-experienced rats. J Neurochem 1991;56:1299–1306.
  175. Panlilio LV, Katz JL, Pickens RW, Schindler CW: Variability of drug self-administration in rats. Psychopharmacology 2003;167:9–19.
  176. Panlilio LV, Schindler CW: Self-administration of remifentanil, an ultra-short acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats. Psychopharmacology (Berl) 2000;150:61–66.
  177. Panlilio LV, Thorndike EB, Schindler CW: Cocaine self-administration under variable-dose schedules in squirrel monkeys. Pharmacol Biochem Behav 2006;84:235–243.
  178. Paronis CA, Holtzman SG: Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists. Psychopharmacology (Berl) 1994;114:601–610.
  179. Parrott AC: Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001;16:557–577.
  180. Paterson NE, Markou A: Increased motivation for self-administered cocaine after escalated cocaine intake. Neuroreport 2003;14:2229–2232.
  181. Pavlov I: Lectures on Conditioned Reflexes. New York, International Publishers, 1928.
  182. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 4. New York, Academic Press, 1998.
  183. Peltier RL, Li DH, Lytle D, Taylor CM, Emmett-Oglesby MW: Chronic D-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. J Pharmacol Exp Ther 1996;277:212–218.
  184. Perkins KA: Chronic tolerance to nicotine in humans and its relationship to tobacco dependence. Nicotine Tob Res 2002;4:405–422.
  185. Perkins KA, Gerlach D, Broge M, Grobe JE, Sanders M, Fonte C, Vender J, Cherry C, Wilson A: Dissociation of nicotine tolerance from tobacco dependence in humans. J Pharmacol Exp Ther 2001;296:849–856.
  186. Pettit HO, Pan HT, Parsons LH, Justice JB Jr: Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 1990;55:798–804.
  187. Piazza PV, Deroche V: What juxtaposition, tradition and parsimony can do to vertical shifts in drug self-administration dose-response functions. Psychopharmacology 2004;171:356–359.
  188. Picker MJ, Craft RM, Negus SS, Powell KR, Mattox SR, Jones SR, Hargrove BK, Dykstra LA: Intermediate efficacy μ opioids: examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats. J Pharmacol Exp Ther 1992;263:668–681.
  189. Preuss UW, Schuckit MA, Smith TL, Danko GR, Dasher AC, Hesselbrock MN, Hesselbrock VM, Nurnberger JI Jr: A comparison of alcohol-induced and independent depression in alcoholics with histories of suicide attempts. J Stud Alcohol 2002;63:498–502.
  190. Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ: One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988;45:977–986.
  191. Richardson NR, Roberts DC: Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 1996;66:1–11.
  192. Riviere GJ, Gentry WB, Owens SM: Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 2000;292:1042–1047.
  193. Roberts DC, Brebner K, Vincler M, Lynch WJ: Patterns of cocaine self-administration in rats produced by various access conditions under a discrete trials procedure. Drug Alcohol Depend 2002;67:291–299.
  194. Roberts DC, Jungersmith KR, Phelan R, Gregg TM, Davies HM: Effect of HD-23, a potent long acting cocaine-analog, on cocaine self-administration in rats. Psychopharmacology (Berl) 2003;167:386–392.
  195. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247–291.
  196. Robinson TE, Berridge KC: Incentive-sensitization and addiction. Addiction 2001;96:103–114.
  197. Robinson TE, Berridge KC: Incentive-sensitization and drug ‘wanting’. Psychopharmacology 2004;17:352–353.

    External Resources

  198. Robinson TE, Gorny G, Savage VR, Kolb B: Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats. Synapse 2002;46:271–279.
  199. Salamone JD, Correa M: Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 2002;137:3–25.
  200. Satel SL, Southwick SM, Gawin FH: Clinical features of cocaine-induced paranoia. Am J Psychiatry 1991;148:495–498.
  201. Sato M, Chen CC, Akiyama K, Otsuki S: Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983;18:429–440.
  202. Sawe J: High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 1986;11:87–106.
  203. Schlaepfer TE, Strain EC, Greenberg BD, Preston KL, Lancaster E, Bigelow GE, Barta PE, Pearlson GD: Site of opioid action in the human brain: mu and kappa agonists’ subjective and cerebral blood flow effects. Am J Psychiatry 1998;155:470–473.
  204. Schoenbaum G, Roesch MR, Stalnaker TA: Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci 2006;29:116–124.
  205. Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL: Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry 1997;154:948–957.
  206. Sell LA, Morris JS, Bearn J, Frackowiak RS, Friston KJ, Dolan RJ: Neural responses associated with cue evoked emotional states and heroin in opiate addicts. Drug Alcohol Depend 2000;60:207–216.
  207. Shaham Y, Shalev U, Lu L, deWit H, Stewart J: The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003;168:3–20.
  208. Shizgal P: Neural basis of utility estimation. Curr Opin Neurobiol 1997;7:198–208.
  209. Silva MT, Heyman GM: Chronic morphine consumption decreases wheel running and wheel running-reinforced behavior in rats. Pharmacol Biochem Behav 2001;69:51–57.
  210. Silverman K, Kirby KC, Griffiths RR: Modulation of drug reinforcement by behavioral requirements following drug ingestion. Psychopharmacology (Berl) 1994;114:243–247.
  211. Sim LJ, Selley DE, Dworkin SI, Childers SR: Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 1996;16:2684–2692.
  212. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ: Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 2000;20:4555–4562.
  213. Sizemore GM, Co C, Koves TR, Martin TJ, Smith JE: Time-dependent recovery from the effects of 6-hydroxydopamine lesions of the rat nucleus accumbens on cocaine self-administration and the levels of dopamine in microdialysates. Psychopharmacology (Berl) 2004;171:413–420.
  214. Sizemore GM, Martin TJ: Toward a mathematical description of dose-effect functions for self-administered drugs in laboratory animal models. Psychopharmacology (Berl) 2000;153:57–66.
  215. Skinner BF: Science and the Human Behavior. New York, Macmillan Publishing Co, 1953.
  216. Solomon RL, Corbit JD: An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol Rev 1974;81:119–145.
  217. Spiga S, Puddu MC, Pisano M, Diana M: Morphine withdrawal-induced morphological changes in the nucleus accumbens. Eur J Neurosci 2005;22:2332–2340.
  218. Spragg SDS: Morphine addiction in chimpanzees. Comp Psychol Monogr 1940;15:5–132.
  219. Stewart J, de Wit H, Eikelboom R: Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. Psychol Rev 1984;91:251–268.
  220. Strakowski SM, Sax KW, Setters MJ, Keck PE Jr: Enhanced response to repeated D-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry 1996;40:872–880.
  221. Suto N, Austin JD, Tanabe LM, Kramer MK, Wright DA, Vezina P: Previous exposure to VTA amphetamine enhances cocaine self-administration under a progressive ratio schedule in a D1 dopamine receptor dependent manner. Neuropsychopharmacology 2002;27:970–979.
  222. Suto N, Tanabe LM, Austin JD, Creekmore E, Vezina P: Previous exposure to VTA amphetamine enhances cocaine self-administration in an NMDA, AMPA/kainate and metabotropic glutamate receptor dependent manner. Neuropsychopharmacology 2003;28:629–639.
  223. Tennant F, Shannon J: Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations. J Addict Dis 1995;14:67–74.
  224. Thompson T, Schuster CR: Morphine self-administration, food-reinforced, and avoidance behaviors in rhesus monkeys. Psychopharmacologia 1964;5:87–94.
  225. Trinkoff AM, Ritter C, Anthony JC: The prevalence and self-reported consequences of cocaine use: an exploratory and descriptive analysis. Drug Alcohol Depend 1990;26:217–225.
  226. Tsibulsky VL, Norman AB: Satiety threshold: a quantitative model of maintained cocaine self-administration. Brain Res 1999;839:85–93.
  227. Tsibulsky VL, Norman AB: Real time computation of in vivo drug levels during drug self-administration experiments. Brain Res Brain Res Protoc 2005;15:38–45.
  228. Uslaner JM, Acerbo MJ, Jones SA, Robinson TE: The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine. Behav Brain Res 2006;169:320–324.
  229. Vanderschuren LJ, Everitt BJ: Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 2004;305:1017–1019.
  230. Vermeire A, Remon JP, Rosseel MT, Belpaire F, Devulder J, Bogaert MG: Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients. Eur J Clin Pharmacol 1998;53:325–330.
  231. Vezina P: Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 2004;27:827–839.
  232. Vezina P, Lorrain DS, Arnold GM, Austin JD, Suto N: Sensitization of midbrain dopamine neuron reactivity promotes the pursuit of amphetamine. J Neurosci 2002;22:4654–4662.
  233. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N: Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830–833.
  234. Wachtel SR, deWit H: Subjective and behavioral effects of repeated D-amphetamine in humans. Behav Pharmacol 1999;10:271–281.
  235. Wakonigg G, Sturm K, Saria A, Zernig G: Opioids, cocaine, and food change runtime distribution in a rat runway procedure. Psychopharmacology 2003;169:52–59.
  236. Walker EA, Richardson TM, Young AM: Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats. Psychopharmacology (Berl) 1997;133:17–28.
  237. Ward SJ, Lack C, Morgan D, Roberts DC: Discrete-trials heroin self-administration produces sensitization to the reinforcing effects of cocaine in rats. Psychopharmacology (Berl) 2006;185:150–159.
  238. Wee S, Specio SE, Koob GF: Effects of dose and session duration on cocaine self-administration in rats. J Pharmacol Exp Ther 2007;320:1134–1143.
  239. Weeks JR: Experimental morphine addiction: method for automatic intravenous injections in unrestrained rats. Science 1962;12:143–144.

    External Resources

  240. Weiss F, Koob GF: Drug addiction: functional neurotoxicity of the brain reward systems. Neurotox Res 2001;3:145–156.
  241. Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC: Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry 2001;158:86–95.
  242. Wikler A: A psychodynamic study of a patient during experimental self-regulated re-addiction to morphine. Psychiatric Q 1952;26:270–293.
  243. Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL: On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology (Berl) 2000;153:139–147.
  244. Winger G, Palmer RK, Woods JH: Drug-reinforced responding: rapid determination of dose-response functions. Drug Alcohol Dep 1989;24:135–142.
  245. Winger G, Skjoldager P, Woods JH: Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 1992;261:311–317.
  246. Winger G, Woods JH: The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alcohol Dep 2001;62:181–189.
  247. Wise RA, Newton P, Leeb K, Burnette B, Pocock D, Justice JB: Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology 1995;120:10–20.
  248. Wise RA, Yokel RA, deWit H: Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science 1976;191:1273–1275.
  249. Wood DM, Emmett-Oglesby MW: Characteristics of tolerance, recovery from tolerance and cross-tolerance for cocaine used as a discriminative stimulus. J Pharmacol Exp Ther 1986;237:120–125.
  250. Wood DM, Lal H, Emmett-Oglesby M: Acquisition and recovery of tolerance to the discriminative stimulus properties of cocaine. Neuropharmacology 1984;23:1419–1423.
  251. Woods JH, Winger G, France CP: Use of in vivo apparent pA2 analysis in assessment of opioid abuse liability. Trends Pharmacol Sci 1992;13:282–286.
  252. Woolverton WL, Nader MA: Experimental evaluation of the reinforcing effects of drugs. Mod Method Pharmacol 1990;165–192.
  253. Woolverton WL, Weiss SRB: Tolerance and sensitization to cocaine: an integrated view; in Higgins ST, Katz JL (eds): Cocaine Abuse. Behavior, Pharmacology, and Clinical Applications. San Diego, Academic Press, 1998.
  254. World Health Organisation: Tenth revision of the international classification of diseases (ICD-10). Geneva, World Health Organisation, 1992.
  255. Wyvell CL, Berridge KC: Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward ‘wanting’ without enhanced ‘liking’ or response reinforcement. J Neurosci 2000;20:8122–8130.
  256. Yanagita T: An experimental framework for evaluation of dependence liability of various types of drugs in monkeys. Bull Narcotics 1973;25:57–64.
  257. Young AM, Sannerud CA, Steigerwald ES, Doty MD, Lipinski WJ, Tetrick LE: Tolerance to morphine stimulus control: role of morphine maintenance dose. Psychopharmacology (Berl) 1990;102:59–67.
  258. Zahm DS: An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 2000;24:85–105.
  259. Zernig G, Burke T, Lewis JW, Woods JH: Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays. J Pharmacol Exp Ther 1996;279:23–31.
  260. Zernig G, Butelman ER, Lewis JW, Walker EA, Woods JH: In vivo determination of mu opiod receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 1994;269:57–65.
  261. Zernig G, Giacomuzzi S, Riemer Y, Wakonigg G, Sturm K, Saria A: Intravenous drug injection habits: drug users’ self-reports versus researchers’ perception. Pharmacology 2003;68:49–56.
  262. Zernig G, Issaevitch T, Woods JH: Calculation of agonist efficacy, apparent affinity and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches. J Pharmacol Toxicol Methods 1996;35:223–237.
  263. Zernig G, Lewis JW, Woods JH: Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology 1997;129:233–242.
  264. Zernig G, Saria A, Krassnig R, Schmidhammer H: Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon. Life Sci 2000;66:1871–1877.
  265. Zernig G, Saria A, Kurz M, O’Malley SS: Handbook of Alcoholism. Boca Raton, CRC Press, 2000.
  266. Zernig G, Wakonigg G, Madlung E, Haring C, Saria A: Do vertical shifts in dose-response rate-relationships in operant conditioning procedures indicate ‘sensitization’ to ‘drug wanting’? Psychopharmacology 2004;171:349–351.
  267. Zittel-Lazarini A, Cador M, Ahmed SH: A critical transition in cocaine self-administration: behavioral and neurobiological implications. Psychopharmacology (Berl) 2007;192:337–346.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50